Recent Updates
Recently added Catalysts
INVA Positive Sentiment

Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026

Monday, October 19, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Innoviva Specialty Therapeutics announced it will present data from four abstracts at IDWeek 2026. This annual meeting, organized by several infectious disease societies, will take place from October 21 to 24, 2026. The presentation aims to highlight advancements in their infectious disease portfolio.

Market Sentiment Analysis

POSITIVE FACTORS

  • Innoviva Specialty Therapeutics will showcase important data.
  • The presentation highlights advancements in infectious disease treatments.
  • Participation in a prominent annual meeting enhances visibility.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
3%
average across 3 past catalysts
Lead asset
AZD0914
Phase 1 · Undisclosed

Full Press Release Details

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today it will present data from four abstracts at IDWeek 2026, the annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). The meeting will be held October 21–24, 2026, at the Walter E. Washington Conventio

Frequently Asked Questions

What is IDWeek 2026?

IDWeek 2026 is the annual meeting of several infectious disease societies.

When will IDWeek 2026 take place?

IDWeek 2026 is scheduled for October 21-24, 2026.

What will Innoviva present at IDWeek 2026?

Innoviva will present data from four abstracts related to infectious diseases.

Who organizes IDWeek?

IDWeek is organized by IDSA, SHEA, HIVMA, and PIDS.

ShareAdd on Google
Tags: INVA Innoviva IDWeek 2026 infectious diseases therapeutics clinical data
Last updated: Oct 19, 2026

Biotech snapshot

Cash runway
$570M liquidity · $0M/mo burn
Low dilution risk
Lead asset
AZD0914Phase 1
Undisclosed →

Catalyst track record

+24%
best trade around INVA's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for INVA.

See every catalyst's timing & PoA →